Astrocyte-derived fibronectin mediates blood-brain barrier breakdown in Alzheimer's disease, particularly in APOE ε4 carriers. This identifies a mechanistic link between genetic risk, amyloid pathology, and vascular dysfunction—opening a therapeutic pathway that addresses neurodegeneration at the level of cerebral perfusion rather than amyloid alone.
Key Points
- Fibronectin from astrocytes drives blood-brain barrier dysfunction in APOE4 carriers
- Links APOE4 genotype and amyloid accumulation to vascular damage directly
- FN1 protein emerges as a viable therapeutic target for intervention
Longevity Analysis
Blood-brain barrier integrity is foundational to cognitive resilience and represents a critical point of intervention that conventional amyloid-focused approaches have largely overlooked. This work decodes a specific molecular signal—fibronectin elevation—that precedes or accompanies neurodegeneration, allowing for earlier detection and more targeted elimination of the vascular dysfunction that propagates cognitive decline. For individuals carrying APOE ε4, this reveals why generic neuroprotective strategies often underperform and points toward the necessity of genotype-informed intervention at the vascular level rather than exclusively at the level of amyloid clearance.
Original published by Nature Aging, by Prabesh Bhattarai.